

ALERTA BIBLIOGRÁFICA y NOTICIAS

Respuesta rápida para casos de
epidemias/pandemias/desastres
naturales

Servicio Especial de la
Biblioteca Médica Nacional

No.30 / 12 mayo 2020



Ensayos clínicos y Tratamientos de la COVID-19

Descriptores DeCS -

MeSH

Ensayos Clínicos como asunto
Infecciones por Coronavirus
/terapia

Clinical Trials as Topic
Coronavirus Infections
/therapy

Bibliografía

Ensayos clínicos

1. **A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Diseases (COVID-19).** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1XGIMM7ooZpDmaFjx8t7rxoX4BWBHs8C/view?usp=drive_web
2. Biblio HULP. **ICTRP COVID-19-trials.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1pcGK_SFKPlk34eni07uu_nx7UJhg_nAl/view?usp=drive_web
3. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. **The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.** Antiviral Research. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.sciencedirect.com/science/article/pii/S0166354220302011>
4. Cassiano O. **Clinicaltrials resultados.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1Tp7D_qfNwJfCzAa2_hSGGsAB6ebSS6U8/view?usp=drive_web
5. García-Puente M. **The FDA-approved Drug Ivermectin inhibits the replication of SARS-1 CoV-2 in vitro.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1FkOHezEWxZAYXDaSBVKiOK9f5u1rDw0z/view?usp=drive_web
6. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. **Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.** International Journal of Antimicrobial Agents. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://doi.org/10.1016/j.ijantimicag.2020.105949>
7. Gaco L. **Prospective registration and reporting of trial number in randomised clinical trials_global cross sectional study of the adoption of ICMJE and Declaration of Helsinki recommendations.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/19-Oe3mrPnqNY7z2Ct8mz_zDVju4R5dKM/view?usp=drive_web

8. Keshtkar-Jahromi M, Bavari S. **A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).** The American Journal of Tropical Medicine and Hygiene [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0230>
9. Rebeca Isabel. **EU_clinicaltrial.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1U50WquLwHvnWfXWmZQc2F9knGOZWgLG6Y/view?usp=drive_web
10. Rebeca Isabel. **Hydroxychloroquine and azithromycin as a treatment of COVID.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1pcGK_SFKPlk34eni07uu_nx7UJhg_nAl/view?usp=drive_web
11. Redondo JC. **SARS-CoV-2 Seroconversion in Humans- A Detailed Protocol for a Serological Assay, Antigen Production, and Test.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1Luvv6SL2m6ut9U-XddrmrC4MhWXdkDMX/view?usp=drive_web
12. Vivas M. **Clinicaltrials.gov COVID19.xlsx.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1nybZhppSB_tbBKncM8XTkMXJlk7m1J4o/view?usp=drive_web

Células Madre

13. Atluri S, Manchikanti L, Hirsch JA. **Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.** Pain Physician. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1Bq-lu9fY6MsKxf30L-vafL_3Q8e3GMaT/view?usp=drive_web
14. Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, et al. **Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment.** Engineering (Beijing). [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1cYAVnTln_3tkxXY7K6taUrYMMDwn096S/view?usp=drive_web
15. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. **Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.** Aging Dis. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en:

https://drive.google.com/file/d/1EjcQhL3w2dz8dxwDPOG6vP74JYBcrf2R/view?usp=drive_web

16. Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. **Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells**. ChinaXiv. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1PeKzRfp-pf_Gpn1-bGic8DYxJTshHfuh/view?usp=drive_web
17. NICE. Overview | **COVID-19 Rapid Guideline: Haematopoietic Stem Cell Transplantation**. Guidance[Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1WeCROumRMvcwq24wtYz_leP-6Phq5nIj/view?usp=drive_web
18. Sahu KK, Mishra AK, Lal A. **Comprehensive update on current outbreak of novel coronavirus infection (2019-nCoV)**. Ann Transl Med. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1oOn62gKzxBwu9OJfGS7-vOw87lwBfs7/view?usp=drive_web

Tocilizumab

19. Cai X. **An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis** [Internet]. Open Science Framework. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://osf.io/hw34x>
20. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. **Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)** [Internet]. Infectious Diseases (except HIV/AIDS). [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://medrxiv.org/lookup/doi/10.1101/2020.02.18.20024364>
21. Liu T, Zhang J, Yang Y, Zhang L, Ma H, Li Z, et al. **The Potential Role of IL-6 in Monitoring Coronavirus Disease 2019**. SSRN Journal [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.ssrn.com/abstract=3548761>
22. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. **Tocilizumab treatment in COVID-19: A single center experience**. J Med Virol [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://doi.wiley.com/10.1002/jmv.25801>
23. Qiu R, Wei X, Zhao M, Zhong C, Zhao C, Hu J, et al. **Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review** [Internet]. Public and Global Health [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://medrxiv.org/lookup/doi/10.1101/2020.03.04.20031401>
24. Zhang Q, Wang Y, Qi C, Shen L, Li J. **Clinical trial analysis of 2019-nCoV therapy registered in China**. J Med Virol. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://doi.org/10.1002/jmv.25733>

25. Zhang Q, Wang Y, Qi C, Shen L, Li J. **Response to Comments on Zhang et al_Clinical trial analysis of 2019-nCoV therapy registered in China.** J. of Med Virol. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25803>

Tratamiento

26. **American Academy of Dermatology Association (ADD). Guidance on the use of biologic agents during COVID-19 outbreak_AAD.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://assets.ctfassets.net/1ny4yoiryqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics and COVID-19.pdf](https://assets.ctfassets.net/1ny4yoiryqia/PicgNuD0IpYd9MSOwab47/023ce3cf6eb82cb304b4ad4a8ef50d56/Biologics_and_COVID-19.pdf)
27. **American College of Rheumatology. Guiding Principles from American College of Rheumatology for Scarce Resource Allocation During COVID-19 Pandemic. The case of Hydroxychloroquine** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.rheumatology.org/Portals/0/Files/Guiding-Principles-Scarce-Resource-Allocation-During-COVID-19.pdf>
28. Bauman JL, Tisdale JE. **Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity.** Pharmacotherapy [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://doi.wiley.com/10.1002/phar.2387>
29. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Chi-Chung Cheng V. **Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19.** Infectious Diseases Society of America. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.idsociety.org/globalassets/idsa/practice-guidelines/COVID-19/treatment/idsa-COVID-19-gl-tx-and-mgmt-v1.0.4.pdf>
30. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Chi-Chung Cheng V. **Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19.** Infectious Diseases Society of America. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.idsociety.org/globalassets/idsa/practice-guidelines/COVID-19/treatment/idsa-COVID-19-gl-tx-and-mgmt-v1.0.4.pdf>
31. **Chloroquine and Hydroxychloroquine in the Era of SARS – CoV2: Caution on Their Cardiac Toxicity.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://doi.wiley.com/10.1002/phar.2387>
32. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. **A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19.** N Engl J Med. 18 de marzo de 2020; NEJM. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.nejm.org/doi/full/10.1056/NEJMoa2001282>

33. Coiras M, Alcamí J, Plaza JA. **Necesidad de encontrar fármacos frente a la enfermedad COVID-19** [Internet]. Instituto de Salud Carlos III (ISC). [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://bit.ly/2KSijch>
34. Covid M-A. **Can antimalarials be used to treat COVID-19?** [Internet]. Ministry of Health Singapore. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [http://www.ace-hta.gov.sg/public-data/COVID-19-resources/Antimalarials%20for%20COVID-19%20\(25%20March%202020\).pdf](http://www.ace-hta.gov.sg/public-data/COVID-19-resources/Antimalarials%20for%20COVID-19%20(25%20March%202020).pdf)
35. **Cascada del complemento en pacientes con COVID-19.** Sociedad Española de Inmunología. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.inmunologia.org/Upload/Documents/1/5/2/1526.pdf>
36. Covid M-A. **Should ACE inhibitors and angiotensin II receptor blockers be stopped for COVID-19?** Ministry of Health Singapore. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/ace-i-and-arb-in-COVID-19-\(21-march-2020\).pdf](https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/ace-i-and-arb-in-COVID-19-(21-march-2020).pdf)
37. Covid M-A. **Should baricitinib be used for COVID-19?** [Internet]. Ministry of Health Singapore. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://bit.ly/2ybGnA4>
38. Covid MA, Ministry of Health Singapore. **Should convalescent plasma be used for COVID-19?** Ministry of Health Singapore. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/convalescent-plasma-infusion-for-COVID-19-\(updated-27-march-2020\).pdf](https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/convalescent-plasma-infusion-for-COVID-19-(updated-27-march-2020).pdf)
39. Covid MA. **Should favipiravir be used for COVID-19?** Ministry of Health Singapore. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/favipiravir-for-COVID-19-\(updated-28-april-2020\).pdf](https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/favipiravir-for-COVID-19-(updated-28-april-2020).pdf)
40. Covid MA. **Should ibuprofen be used for COVID-19?** Ministry of Health Singapore. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/ibuprofen-in-COVID-19-\(21-march-2020\).pdf](https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/ibuprofen-in-COVID-19-(21-march-2020).pdf)
41. Covid MA. **Should interleukin-6 (IL-6) inhibitors be used for COVID-19?** Ministry of Health Singapore. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/il-6-inhibitors-in-COVID-19-for-moh-publication-\(updated-27-march-2020\).pdf](https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/il-6-inhibitors-in-COVID-19-for-moh-publication-(updated-27-march-2020).pdf)
42. Covid MA. **Should remdesivir be used for COVID-19?** Ministry of Health Singapore, [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/remdesivir-for-COVID-19-\(updated-13-april-2020\).pdf](https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/remdesivir-for-COVID-19-(updated-13-april-2020).pdf)

43. **¿Cuál es la eficacia de la hidroxiclороquina en el tratamiento de la COVID-19?** Cochrane Iberoamericana. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://mmrjournal.biomedcentral.com/articles/10.1186/s40779-020-0233-6>
44. **Desempeño clínico de las pruebas diagnósticas de laboratorio en la infección por SARS-CoV-2.** Universidad de Antioquia. Unidad de Evidencia y Deliveración para la toma de decisiones-UNED. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://drive.google.com/file/d/1CRXVy7yysFCY1_9FFWyFdjCzaxxD2IMq/view
45. **Evaluating the drug-drug interaction risk of experimental COVID-19 therapies** [Internet]. Liverpool Drug Interactions Group. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://go.aws/2xqi9ls>
46. **Experimental COVID-19 Therapies Administration in Cases of Swallowing Difficulties.** Liverpool Drug Interaction Group; [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [Experimental COVID-19 Therapies Administration in Cases of Swallowing Difficulties](#)
47. Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al. **Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.** The Lancet. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://doi.org/10.1016/S0140-6736\(20\)30858-8](https://doi.org/10.1016/S0140-6736(20)30858-8)
48. Ferner RE, Aronson JK. **Remdesivir in COVID-19.** BMJ. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://doi.org/10.1136/bmj.m1610>
49. Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. **Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.** J Intern AIDS Soc [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jia2.25489>
50. García E. **Evidencia disponible de los fármacos utilizados en pacientes con COVID-19 (I). Corticoides sistémicos.** Ojo de Markov Portal del Medicamento Salud Castilla y León. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://bit.ly/2WfCJNx>
51. García E, Caro-Patón T. **Evidencia disponible de los fármacos utilizados en pacientes con COVID-19 (II) Hidroxiclороquina y azitromicina.** Ojo de Markov Portal del Medicamento Salud Castilla y León. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://bit.ly/3d07o8l>
52. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O'Meara MJ, et al. **A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing** [Internet]. Systems Biology. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://biorxiv.org/lookup/doi/10.1101/2020.03.22.002386>

53. Groneberg D, Poutanen S, Low D, Lode H, Welte T, Zabel P. **Treatment and vaccines for severe acute respiratory syndrome.** The Lancet Infectious Diseases. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://doi.org/10.1016/S1473-3099\(05\)01307-1](https://doi.org/10.1016/S1473-3099(05)01307-1)
54. Heneghan C, Aronson J, Ferner R, DeVito NJ. **COVID-19 trials registered up to 8 March 2020—an analysis of 382 studies.** CEBM. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.cebm.net/wp-content/uploads/2020/03/COVID-19-registered-trials%E2%80%94an-analysis-1.pdf>
55. Instituto para el Uso Seguro de los Medicamentos (ISMP-España). **Boletín de Recomendaciones para la prevención de errores de medicación** [Internet]. Ministerio de Sanidad. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://www.ismp-espana.org/ficheros/Boletin%2049%20%28Abril%202020%29.pdf>
56. **Interactions with Experimental COVID-19 Therapies** [Internet]. Liverpool Drug Interactions Group. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://go.aws/3bMKGjY>
57. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. **A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19.** Crit Care. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponib
58. Martín Ponce ML. **Interacciones Fármacos COVID19 (Lopi/Rito +/- HDQ) [Internet]. UGC Medicina Interna.** Hospital V. Valme. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://udmfycofradelicias.blogspot.com/2020/03/ugc-mi-hv-valme-interacciones-farmacos.html>
59. Sainz Navarro, Luis Carlos. **Cloroquina e hidroxicloroquina como potenciales terapias frente al COVID-19.** Servicio Navarro de Salud. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: http://www.navarra.es/NR/rdonlyres/6EAA15A8-75D9-4C43-B218-98D590FC247D/460707/Informecloroquina_hidroxicloroquinaparaCOVID_19170.pdf
60. Touyz RM, Li H, Delles C. **ACE2 the Janus-faced protein – from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19.** Clinical Science. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://doi.org/10.1042/CS20200363>
61. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. **Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.** J Thromb Haemost [Internet]. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://doi.wiley.com/10.1111/jth.14817>
62. Tiberghien P, de Lambalerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. **Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how.** Vox Sang. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://doi.wiley.com/10.1111/vox.12926>

63. Universidad de Antioquia., Medellín; Unidad de Evidencia y Deliberación para la Toma de Decisiones-UNED. Facultad de Medicina, Universidad de Antioquia. **Intervenciones no farmacológicas para la contención, mitigación y supresión de la infección por COVID-19.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: http://docs.bvsalud.org/biblioref/2020/04/1087642/udea-uned_sintesisrapida_covid19_ncov19_nofarmacologicas_rapid_gvdw72U.pdf
64. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. **Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications** [Internet]. Infectious Diseases (except HIV/AIDS). [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://medrxiv.org/lookup/doi/10.1101/2020.03.30.20047365>
65. **Optimizing Medication Management during the COVID-19 Pandemic: Implementation Guide for Post-Acute and Long-Term Care.** University of Maryland. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/lamy/covid19-med-mgmt/complete-implementation-guide_042420.pdf
66. Perras C. **Remdesivir.** Ottawa: CADTH. (COVID-19 CADTH Health Technology Review). [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://cadth.ca/sites/default/files/COVID-19/covid-remdesivir.pdf>
67. **Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).** Asian Pac J Allergy Immunol [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: http://apjai-journal.org/wp-content/uploads/2020/03/5_AP-200220-0773.pdf
68. **Protocolo Tratamiento según gravedad y evolución COVID19** [Internet]. Hospital Universitario de Móstoles. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.stefajir.cz/files/Protocolo-Tratamiento-COVID19-HUM-V4-08-04-20.pdf>
69. **Recomanacions de tractament farmacològic en la infecció per SARS-CoV-2 en l'àmbit extrahospitalari.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: http://gestorweb.camfic.cat/uploads/ITEM_12828_EBLOG_4007.pdf
70. **Recomendaciones de tromboprolifaxis y tratamiento antitrombótico en pacientes con COVID-19.** Sociedad Española de Trombosis y Hemostasia. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.sehh.es/images/stories/recursos/2020/03/covid/22/Recomendaciones-tromboprolifaxis-y-tratamiento-antitrombotico-pacientes-COVID-19.pdf>
71. **Recomendaciones para la obtención de plasma de donantes convalecientes de la enfermedad del Coronavirus SARS-CoV (COVID19).** Madrid: Ministerio de Sanidad. Comité Científico Seguridad Transfusional. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://bit.ly/2VP1aCu>

72. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. **Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.** JAMA [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://jamanetwork.com/journals/jama/fullarticle/2764727>
73. Sarayani A, Cicali B, Henriksen CH, Brown JD. **Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.** Research in Social and Administrative Pharmacy. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://www.ncbi.nlm.gov/pmc/articles/PMC7166303>
74. Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. **Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis.** J Med Virol. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://doi.org/10.1002/jmv.25898>
75. Sarkar B, Ullah MdA, Johora FT, Taniya MA, Araf Y. **The Essential Facts of Wuhan Novel Coronavirus Outbreak in China and Epitope-based Vaccine Designing against COVID-19** Immunology. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://biorxiv.org/lookup/doi/10.1101/2020.02.05.935072>
76. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. **Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.** JAMA [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://jamanetwork.com/journals/jama/fullarticle/2763983>
77. **Should protease inhibitors be used for COVID-19.** Ministry of Health Singapore. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: [https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/protease-inhibitors-for-COVID-19-\(updated-14-april-2020\).pdf](https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-summaries/protease-inhibitors-for-COVID-19-(updated-14-april-2020).pdf)
78. **Some drugs being considered for treatment of COVID—19.** The Medical Letter on [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://secure.medicalletter.org/downloads/1595e_table.pdf
79. Thachil J. **The versatile heparin in COVID-19.** J Thromb Haemost [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <http://doi.wiley.com/10.1111/jth.14821>
80. Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, et al. **Type and dose of heparin in COVID-19.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://doi.org/10.1111/jth.14870>
81. **Temas de interés sobre: Medicamentos y COVID-19; Tratamientos del COVID-19; Flozinas** CADIME. Centro Andaluz de Documentación e Información de Medicamentos. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://cadime.es/noticias/ultimas-noticias/120-noticias-COVID-19/692-temas-de-interés-sobre-medicamentos-y-COVID-19-tratamientos-del-COVID-19-flozinas.html>

82. **Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2.** Agencia Española de Medicamentos. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.aemps.gob.es/laAEMPS/docs/medicamentos-disponibles-SARS-CoV-2-28-3-2020.pdf?x47154>
83. **Tratamiento farmacológico de la infección COVID-19 en adultos. Síntesis rápida** [Internet]. Universidad de Antioquia. Unidad de Evidencia y Deliberación para la toma de decisiones-UNED. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: https://es.cochrane.org/sites/es.cochrane.org/files/public/uploads/COVID-19/udea-uned_sintesisrapida_covid19_ncov19_tratamiento_rapissynthesis_covid19_ncov19_treatment_06abril2020.pdf
84. **Treatment Algorithm for Hospitalized Adults with Non–Severe COVID-19_YNHHS** Yale New Haven Health. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.rivm.nl/sites/default/files/2020-04/YNHHS%20Treatment%20Algorithm%20for%20Hospitalized%20Adults%20with%20Non–Severe%20COVID-19.pdf>
85. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. **Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China.** Infectious Diseases (except HIV/AIDS). [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en:<http://medrxiv.org/lookup/doi/10.1101/2020.03.06.20032342>
86. Yao T, Qian J, Zhu W, Wang Y, Wang G. **A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease-19 treatment option.** J Med Virol. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://doi.org/10.1002/jmv.25729>
87. Yazdany J, Kim AHJ. **Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.** Ann Intern Med [Internet]. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://annals.org/aim/fullarticle/2764199/use-hydroxychloroquine-chloroquine-during-COVID-19-pandemic-what-every-clinician>
88. Zhejiang University School of Medicine. **Handbook of COVID-19 Prevention and Treatment.** [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://www.alnap.org/help-library/handbook-of-COVID-19-prevention-and-treatment>
89. Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM), Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, et al. **A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).** Military Med Res. [Internet]. 2020 [citado 11 May 2020];20:[aprox. 10 p.]. Disponible en: <https://mmrjournal.biomedcentral.com/track/pdf/10.1186/s40779-020-0233-6>

Compilación: Dra.C. Maria del Carmen González Rivero

Noticias

1. **Aprueban ensayos clínicos de vacunas contra la COVID-19 en Alemania.** Cluster 23 abr. 2020 Alemania dio luz verde a los ensayos en humanos de posibles vacunas contra el coronavirus desarrolladas por la... [Leer más](#)
2. **BioCubaFarma: Resultados alentadores en ensayos clínicos para tratar a la COVID-19.** 22 abr. 2020 · BioCubaFarma: Resultados alentadores en ensayos clínicos para tratar a pacientes con la COVID-19. Resultado ... [Leer más](#)
3. **Cuba continúa ensayo clínico de nuevos medicamentos contra la COVID-19.** La Habana, 20 abr (Prensa Latina) Científicos y especialistas en salud de Cuba continúan hoy los ensayos clínicos de nuevos... [Leer más](#)
4. **Ensayos clínicos y COVID-19. National Kidney Foundation.** Si todavía no está inscrito en un ensayo clínico, probablemente deba esperar a que la pandemia de la COVID-19 esté controlada antes... [Leer más](#)
5. **Ensayo clínico Solidaridad sobre tratamientos contra la COVID-19.** Todavía no se ha demostrado que pueda mejorar los resultados clínicos o prevenir la infección en el caso de la COVID-19, MERS y SARS... [Leer más](#)
6. **Ensayos clínicos COVID-19 ¿Sabes lo que es un ensayo clínico?** AMIIF. hace 6 días · No hay una vacuna disponible contra las infecciones por coronavirus del síndrome respiratorio agudo severo ... [Leer más](#)
7. **OMS informa: Tres vacunas de la COVID-19 están en ensayos clínicos y...**16 abr. 2020. Por otro lado, la portavoz del organismo, Margaret Harris, advirtió este martes que una vacuna contra el coronavirus no ... [Leer más](#)
8. **Resultados de la Web. Evidencias COVID-19 | Cochrane Iberoamérica.** Ensayos clínicos de la COVID-19: comentarios estructurados de los ensayos clínicos publicados de tratamientos en pacientes con COVID-19... [Leer más](#)

Compilación: Dra.C. Maria del Carmen González Rivero

Equipo [Bibliografía](#) y DSI de la Biblioteca Médica Nacional.
Dra.C. [Maria del Carmen González Rivero](#) / Lic. [Sonia Santana Arroyo](#)/
Dirección: Lic. [Yanet Lujardo Escobar](#)